Ignite Creation Date:
2024-05-06 @ 10:10 AM
Last Modification Date:
2024-10-26 @ 12:26 PM
Study NCT ID:
NCT03188705
Status:
COMPLETED
Last Update Posted:
2023-06-15
First Post:
2017-06-14
Brief Title:
CES1 Carriers in the PAPI Study
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Enrichment of CES1 Carriers in the Pharmacogenomics Anti-Platelet Intervention Study
Status:
COMPLETED
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study builds in part upon preliminary results generated as part of the Pharmacogenomics Anti-Platelet Intervention PAPI Study NCT00799396 The purpose of this investigation is to assess the impact of genetic variation in the carboxylesterase 1 CES1 on response to clopidogrel as well as dual antiplatelet therapy ie clopidogrel and aspirin as assessed by ex vivo platelet aggregometry in healthy Amish individuals The investigators hypothesize that participants who carry alleles that modify the activity or expression of CES1 will have altered response to clopidogrel as well as dual antiplatelet therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None